Q4 2024 Earnings Conference Call February 18, 2025 4:30 PM ETCompany ParticipantsCecilia Furlong - Director of ...

While it's unclear where Wembanyama's clot is located in the shoulder, deep vein thrombosis (DVT) occurs when a blood clot ...

The OCEANIC-AF trial has raised concerns about factor XI inhibitors. Should physicians still bet on this class of ...

Chronic leg problems following DVT include leg heaviness, tiredness, cramping and ulceration. These are termed the post-thrombotic syndrome. The current standard therapy of anticoagulation has ...

Penumbra's Q4 2024 EPS and revenue exceeded forecasts. The stock price increased by 7.32% in aftermarket trading. Gross margin improved to 67.4%, up 170 basis points year-over-year. The company ...

In a systematic review and meta-analysis of trials of non-vitamin K oral anticoagulants vs. single antiplatelet therapy, rivaroxaban use corresponded with higher rates of major bleeding compared ...

Penumbra's Q4 2024 EPS and revenue exceeded forecasts. The stock price increased by 7.32% in aftermarket trading. Gross margin improved to 67.4%, up 170 basis points year-over-year. The company ...

AstraZeneca's anticoagulant reversal agent Andexxa was given an accelerated approval by the FDA in 2018, but the company's plan to get that upgraded to a full approval is facing some pushback.

1. Anticoagulant therapy is clearly effective in treating and preventing venous thrombosis and pulmonary emboli. 2. If used in the treatment of acute myocardial infarction, anticoagulant drugs may ...

Correspondence to Dr Justin F Fraser, Neurological Surgery, University of Kentucky, Lexington, KY 40536, USA; Jfr235{at}uky.edu ...